Updated 6yr data #OlympiA by #DrJudyGarber ➡️ continued benefit 12 mon adjuvant #olaparib for gBRCA mut, stage 2/3 or residual cancer post-NACT. 1) further ⬆️ iDFS 9.4% in both #tnbc #ER+ 2) persistent ⬆️ DDFS 7.8%; 3) ⬆️ OS 4.4% 5) ⬇️ CNS Mets, ⬇️ new cancers 6) ↔️ MDS/AML @sabcs.bsky.social #SABCS24